Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan
Journal
Journal of the Formosan Medical Association
Journal Volume
118
Journal Issue
10
Date Issued
2019
Author(s)
Abstract
Hodgkin lymphoma (HL) is a highly curable hematologic malignancy. Relapsed/refractory (R/R) HL is an important clinical challenge, despite advances in treatment. Brentuximab vedotin (BV) is highly effective in R/R HL in the western world. However, there are no real-world data on the use of BV in the Asian population. Our study aimed to evaluate the efficacy and safety of BV as salvage therapy in R/R HL patients in Taiwan. We recruited 20 R/R HL patients who received BV at National Taiwan University Hospital. BV was administered at 1.8 mg/kg once every 3 weeks. The median number of systemic treatment received before BV was three. The overall response rate was 73.7% with a complete remission rate of 21.1% in R/R HL. Overall survival was not reached and progression-free survival was 6.8 months. BV could strengthen disease control before transplantation and improve post-transplant outcomes, even among those heavily pretreated patients, without significant overlapping toxicities with prior therapies. Our data suggest that BV is well tolerated and effective in the treatment of Asian patients with R/R HL. BV may offer long-term disease control in selected patients.
Subjects
Brentuximab vedotin; Hodgkin lymphoma; Relapse; Transplantation
SDGs
Other Subjects
brentuximab vedotin; granulocyte colony stimulating factor; hemoglobin; brentuximab vedotin; immunological antineoplastic agent; adult; aged; allogeneic stem cell transplantation; anemia; Article; Asian; autologous stem cell transplantation; cancer chemotherapy; cancer control; clinical article; clinical outcome; cytopenia; drug efficacy; drug safety; drug tolerability; female; hemoglobin blood level; Hodgkin disease; human; male; monotherapy; multiple cycle treatment; neutropenia; overall survival; peripheral neuropathy; positron emission tomography; progression free survival; relapsed refractory Hodgkin lymphoma; remission; retrospective study; salvage therapy; survival prediction; systemic therapy; Taiwan; treatment response; adolescent; adverse event; Hodgkin disease; middle aged; recurrent disease; retreatment; survival rate; very elderly; young adult; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Brentuximab Vedotin; Female; Hodgkin Disease; Humans; Male; Middle Aged; Progression-Free Survival; Recurrence; Retreatment; Salvage Therapy; Survival Rate; Taiwan; Young Adult
Type
journal article